Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 8/20 | 0.68 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PHGDH | O43175 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055970 | 0.89 | KCNMA1 (0.64) | KCNMA1RORCGAAHTTCRHBP | |
| SCHEMBL28069367 | 0.87 | KCNMA1 (0.78) | KCNMA1RORCNPC1LMNATP53 | |
| SCHEMBL7157849 | 0.86 | KCNMA1 (0.72) | KCNMA1RORCNPC1LMNATP53 | |
| SCHEMBL22722274 | 0.83 | KCNMA1 (0.60) | KCNMA1RORCGAAHTTCRHBP | |
| SCHEMBL4045541 | 0.82 | MEN1 (0.65) | RORCNPC1LMNATP53GAA | |
| SCHEMBL7759260 | 0.81 | KCNMA1 (1.00) | KCNMA1NPC1LMNATP53GAA | |
| SCHEMBL8054226 | 0.80 | CRHBP (0.58) | KCNMA1NPC1LMNAHTTCRHBP | |
| SCHEMBL8122020 | 0.80 | NPC1 (0.67) | KCNMA1RORCNPC1LMNATP53 | |
| SCHEMBL7159721 | 0.78 | CRHBP (0.67) | KCNMA1NPC1LMNACRHBPCRHR2 | |
| SCHEMBL27724656 | 0.78 | MEN1 (0.57) | KCNMA1GAAHTTL3MBTL1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
| WO-2006061126-A2 | DIBENZOXAZEPINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | HTR6, BDKRB1, HTR7 | KCNMA1 294/4885RORC 2718/4885NPC1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.